Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 59.78M P/E - EPS this Y 73.70% Ern Qtrly Grth -
Income -48.6M Forward P/E -0.79 EPS next Y -140.30% 50D Avg Chg -21.00%
Sales 52.16M PEG -0.13 EPS past 5Y - 200D Avg Chg -23.00%
Dividend N/A Price/Book 0.50 EPS next 5Y 14.50% 52W High Chg -62.00%
Recommedations 1.80 Quick Ratio 3.58 Shares Outstanding 9.66M 52W Low Chg 13.00%
Insider Own 21.44% ROA -20.10% Shares Float 6.95M Beta 0.83
Inst Own 36.53% ROE -48.99% Shares Shorted/Prior 51.47K/26.77K Price 0.77
Gross Margin -62.05% Profit Margin -93.16% Avg. Volume 1,394,283 Target Price 44.80
Oper. Margin -1,736.74% Earnings Date Nov 7 Volume 420,646 Change -2.02%
About HOOKIPA Pharma Inc.

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-200 for the treatment of pembrolizumab which is in Phase 2 of clinical trial; HB-700, a preclinical development for treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers. Its lead product candidates are HB-400 for the treatment of Hepatitis B which is in Phase I of clinical trial and HB-500 for the treatment of HIV which is in Phase I of clinical trial. The company's preclinical stage products include HB-300 program for prostate cancer. It has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.

HOOKIPA Pharma Inc. News
11/17/24 Companies Like HOOKIPA Pharma (NASDAQ:HOOK) Could Be Quite Risky
11/17/24 HOOKIPA Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
11/14/24 HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates
11/11/24 HOOKIPA Pharma’s Eseba-vec Highlighted in SITC Late-Breaker
10/31/24 HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024
10/30/24 HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer
09/24/24 HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset
09/02/24 Wall Street Analysts Think HOOKIPA Pharma (HOOK) Could Surge 622.75%: Read This Before Placing a Bet
08/30/24 HOOKIPA Pharma Announces Board of Directors Changes
08/28/24 HOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
08/11/24 HOOKIPA Pharma Second Quarter 2024 Earnings: Revenues Miss Expectations
08/08/24 HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
08/07/24 Wall Street Analysts Believe HOOKIPA Pharma (HOOK) Could Rally 634.38%: Here's is How to Trade
08/01/24 Will HOOKIPA Pharma Inc. (HOOK) Report Negative Q2 Earnings? What You Should Know
07/22/24 HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
07/08/24 HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split
07/02/24 HOOKIPA Pharma doses first subject in Phase Ib HIV treatment trial
07/01/24 HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV
06/04/24 HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
05/30/24 HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting
HOOK Chatroom

User Image 809capital Posted - 43 minutes from now

$HOOK wow!!! I sold at $5.50 posted it here and got haters hating. Red flag when you see CeO and CFO leaving and bunch of directors.

User Image terumodoc Posted - 21 minutes from now

$HOOK No reason to sell at this point..... might as well hold on and hope for the best.

User Image THE_ORJINAL Posted - 21 minutes from now

$HOOK Trading at half the value of cash on hand. Sad story of great technology but poor management. sure what can turn the ship around at this point except a hail mary partnership or being relegated to managing only the GILD programs.

User Image anachartanalyst Posted - 3 hours ago

$HOOK https://anachart.com/wp-content/uploads/ana_temp/1732194096_soc-img.jpg

User Image DonCorleone77 Posted - 4 hours ago

$HOOK $GILD Hookipa Pharma announces workforce reduction of 80%, pause of eseba-vec program In a regulatory filing on Wednesday, Hookipa Pharma (HOOK) announced that on November 18, the company approved a plan to continue to improve its cost structure and operating efficiency, which includes a reduction in the company's workforce by approximately 80% of the company's then-current employee base. The company expects to begin the implementation of the Restructuring Plan in the fourth quarter of 2024 and expects the Restructuring Plan to be substantially completed by the end of the first half of 2025. In connection with the Restructuring Plan, in an effort to rebalance the company's cost structure in alignment with the company's strategic refocus and development of its oncology portfolio, the company also announced that it will pause clinical development in its eseba-vec program for the treatment of Human Papillomavirus 16-positive head and neck cancers, including an early termination of the company's ongoing Phase 1/2 clinical trial for the treatment of HPV16+ cancers. The company's early termination of its ongoing Phase 1/2 clinical trial for the treatment of HPV16+ is not due to lack of efficacy or adverse safety profiles. While the company will continue to seek partnering opportunities for the eseba-vec program, the company will focus primarily on progressing the phase 1-ready HB-700 program for the treatment of KRAS mutant cancers. In April 2024, the Company received Investigational New Drug clearance from the U.S. Food and Drug Administration for HB-700 for the treatment of KRAS mutated cancers, including, lung, colorectal and pancreatic cancers. Notwithstanding the company's Restructuring Plan and the immediate pause of the eseba-vec program, the company continues to enroll patients in its ongoing Phase 1b clinical trial related to its Human Immunodeficiency Virus program, HB-500, being developed in a partnership with Gilead Sciences (GILD). In addition, the company continues to support its Hepatitis B program, HB-400, which is also being developed in a partnership with Gilead.

User Image Hanaleimike Posted - 22 hours ago

$HOOK anyone remember the last Green Day?

User Image Grundle_the_great Posted - 1 day ago

$HOOK volume is still higher. Need some news

User Image Hanaleimike Posted - 2 days ago

$HOOK I don’t understand the super slow decline everyday. At this point everyone is underwater, why the slow parasitic drain. Like hey it’s Monday and it’s down .12 cents. I should sell some. Confused

User Image OurFather Posted - 2 days ago

$HOOK reviewing the operational updates in the latest ER, there are some great opportunities that the company has. The company has made strides on programs that they had to put aside for some time. I believe new partnerships will be announced soon. https://ir.hookipapharma.com/node/9526/pdf

User Image GermanJay Posted - 2 days ago

$HOOK when and how will they raise?

User Image superjeffy Posted - 3 days ago

$HOOK small pharma, no products, all research no money until something is successful and gets government approval. Unless a buyout due to promising developments that big pharma wants.

User Image TangoToEvora Posted - 5 days ago

$HOOK carnage

User Image dcljr521 Posted - 5 days ago

$HOOK from their website.

User Image ShowMeThePar Posted - 5 days ago

$HOOK -50% loss...

User Image Hanaleimike Posted - 6 days ago

$HOOK another new low! They must be busy curing some cancers or something

User Image ShowMeThePar Posted - 6 days ago

$HOOK Wow.. please quickly find partner

User Image GermanJay Posted - 6 days ago

$HOOK Still burning 20 Million/q. Yikes

User Image PenkeTrading Posted - 6 days ago

I found you an Oversold RSI (Relative Strength Index) on the daily chart of Hookipa Pharma Inc. Is that bullish or bearish? $HOOK #Hookipa #RsiOversold #NASDAQ

User Image dcljr521 Posted - 6 days ago

$HOOK finally reporting earnings. Beat estimation.

User Image DonCorleone77 Posted - 6 days ago

$HOOK Hookipa Pharma reports Q3 EPS ($1.10), consensus ($1.90) Reports Q3 revenue $4.7M, consensus $4.95M..."HOOKIPA made excellent progress across each program in our pipeline in the third quarter," said Malte Peters, MD, Chief Executive Officer of HOOKIPA. "We advanced the development of eseba-vec for HPV16+ head and neck squamous cell carcinoma (HNSCC), through the start of an investigator-initiated study in the new clinical setting of adjuvant care, and presented continued positive, updated data from our Phase 2 study in first-line recurrent/metastatic disease as a late breaking abstract at SITC 2024. In parallel, we have made significant progress with our review of the business strategy and operations, having implemented a number of initiatives to optimize spending and ensure prioritization of resources."

User Image Wildsens Posted - 6 days ago

$HOOK Q3: https://ir.hookipapharma.com/news-releases/news-release-details/hookipa-pharma-reports-third-quarter-2024-financial-results-and

User Image d_risk Posted - 6 days ago

$HOOK - HOOKIPA Pharma Inc. Common Stock - 10Q - Updated Risk Factors Major changes: Strategic refocus with workforce cuts for cost savings, risking operational disruptions and talent retention; decreased cash reserves raise funding concerns. #Risk https://d-risk.ai/HOOK/10-Q/2024-11-14

User Image OurFather Posted - 6 days ago

$HOOK sitting with about a $10 average ($1 before RS)…may God have mercy on me lol It looks like the company is doing good things but what are the chances of recovery to $10+ by the end of 2025?

User Image Hanaleimike Posted - 6 days ago

$HOOK anyone buying more in the 2’s$

User Image ButterCapital Posted - 6 days ago

$HOOK adding more

User Image Hanaleimike Posted - 6 days ago

$HOOK even newer lower lowsfuck

User Image dcljr521 Posted - 6 days ago

$HOOK $3 here we come? 😵‍💫

User Image Hanaleimike Posted - 1 week ago

$HOOK new lows. Great job team

User Image TangoToEvora Posted - 1 week ago

$HOOK All time low?

User Image TangoToEvora Posted - 1 week ago

$HOOK wtf

Analyst Ratings
JMP Securities Market Outperform Aug 9, 24
JMP Securities Market Outperform Jul 26, 24
HC Wainwright & Co. Buy Jun 5, 24
RBC Capital Outperform May 21, 24
HC Wainwright & Co. Buy Apr 26, 24
RBC Capital Outperform Mar 25, 24
HC Wainwright & Co. Buy Mar 25, 24
RBC Capital Outperform Jan 30, 24
RBC Capital Outperform Sep 27, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Kandera Reinhard Chief Financial Offi.. Chief Financial Officer Aug 16 Buy 0.714 8,000 5,712 36,092 08/17/23
Aldag Jorn Chief Executive Offi.. Chief Executive Officer Jul 07 Buy 0.82 10,000 8,200 71,952 07/11/23
Aldag Jorn Chief Executive Offi.. Chief Executive Officer Jul 05 Buy 0.89 5,000 4,450 61,952 07/07/23
Matushansky Igor Chief Medical Office.. Chief Medical Officer Dec 21 Option 0.1 22,853 2,285 87,512 01/12/22
Matushansky Igor Chief Medical Office.. Chief Medical Officer Dec 21 Sell 2.49 14,949 37,223 85,307 01/12/22